Argentina's new "epidemiological shield" promises wider investment vision
This article was originally published in Clinica
Argentina has secured funding for the creation of a "national epidemiological shield" (Escudo Epidemiol�gico Argentino, EEA) – an initiative that will not only strengthen disease surveillance, but also have significant impact on the development of the healthcare system generally, reports Chiara Stella Cochetti.
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.